ALLK stock forecast
Our latest prediction for Allakos, Inc.'s stock price was made on the June 7, 2019 when the stock price was at 40.56$.
In the short term (2weeks), ALLK's stock price should underperform the market by -0.76%. During that period the price should oscillate between -9.85% and +10.02%.
In the medium term (3months), ALLK's stock price should outperform the market by 1.41%. During that period the price should oscillate between -21.11% and +26.44%.Get email alerts
About Allakos, Inc.
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.28$ per share.
The book value per share is -1.79$
Three months stock forecastJune 7, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|